Julie J Lee

20040092534, May 13, 2004

Jul 28, 2003

10/629211

Nyomi Yam - Sunnyvale CA, US
Iran Reyes - San Jose CA, US
Nipun Davar - Fremont CA, US
Atul Ayer - Palo Alto CA, US
Julie Lee - Sunnyvale CA, US

A61K031/519

514/259410

Dosage forms and methods for providing a substantially ascending rate of release of paliperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone concentration that occurs following administration of paliperidone in an immediate-release dosage form.

20050208132, Sep 22, 2005

Feb 4, 2005

11/051060

Gayatri Sathyan - San Jose CA, US
Suneel Gupta - Sunnyvale CA, US
Noymi Yam - Sunnyvale CA, US
Iran Reyes - San Jose CA, US
Nipun Davar - Fremont CA, US
Atul Ayer - Palo Alto CA, US
Julie Lee - Sunnyvale CA, US
Sonya Seroff - San Jose CA, US

A61K031/42
A61K009/22

424468000, 514379000

Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient.

20050232995, Oct 20, 2005

Feb 4, 2005

11/051165

Nyomi Yam - Sunnyvale CA, US
Iran Reyes - San Jose CA, US
Nipun Davar - Fremont CA, US
Atul Ayer - Palo Alto CA, US
Julie Lee - Sunnyvale CA, US
Sonya Seroff - San Jose CA, US
Suneel Gupta - Sunnyvale CA, US
Gayatri Sathyan - San Jose CA, US

A61K031/519
A61K009/24

424473000, 514259410

Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

20070166381, Jul 19, 2007

Jan 3, 2007

11/619468

Iran Reyes - San Jose CA, US
Julie Lee - Sunnyvale CA, US
Brian Barclay - Sunnyvale CA, US
Iswadi Liejanto - Redwood City CA, US
Nipun Davar - Fremont CA, US

A61K 9/24

424473000

Disclosed are osmotic dosage forms and methods that provide for fast release of drugs together with controlled release of drugs. In an aspect, disclosed are osmotic dosage forms including: a semi-permeable membrane; a lubricating subcoat located within the semi-permeable membrane; an orifice in the semi-permeable membrane located at an end of the semi-permeable membrane; a drug layer located adjacent to the orifice and within the lubricating subcoat; a push layer located within the lubricating subcoat and on a side of the drug layer opposite from the orifice; wherein an area of the orifice is greater than or equal to about 1,600 mil; and wherein the drug layer comprises from about 20 wt % to about 90 wt % microcrystalline cellulose, and less than or equal to about 10 wt % of a drug, based on the total weight of the drug layer. Also disclosed are methods of making osmotic dosage forms.

20070190137, Aug 16, 2007

Sep 26, 2006

11/528053

Reyes Iran - San Jose CA, US
Julie Lee - Sunnyvale CA, US
Brian Barclay - Sunnyvale CA, US
Nipun Davar - Fremont CA, US
Ramkumar Subramanian - Sunnyvale CA, US

A61K 9/24

424465000

Disclosed are osmotic dosage forms including a semi-permeable membrane; a first and a second orifice in the semi-permeable membrane located at opposite ends of the semi-permeable membrane; a controlled release drug layer located adjacent to the first orifice and within the semi-permeable membrane; a fast release drug layer located adjacent to the second orifice and within the semi-permeable membrane; a push layer located within the semi-permeable membrane and between the controlled release drug layer and the fast release drug layer; a barrier layer slidably located between the push layer and the fast release drug layer; and wherein an area of the second orifice is greater than or equal to about 7800 mil. Also disclosed are methods of making and using such osmotic dosage forms.

20070280856, Dec 6, 2007

Jun 2, 2006

11/422057

Umberto Ulmanella - Foster City CA, US
Eric S. Nordman - Palo Alto CA, US
Maengseok Song - Burlingame CA, US
Joon Mo Yang - Redwood City CA, US
Julie C. Lee - Sunnyvale CA, US
Nigel P. Beard - Redwood City CA, US
Min Yue - Belmont CA, US
Carol Schembri - San Mateo CA, US
David Liu - Los Altos CA, US

APPLERA CORPORATION - Foster City CA

B01L 3/02

422100

A microfluidic device may include a sample distribution network including a plurality of sample chambers configured to be loaded with biological sample for biological testing of the biological sample while in the sample chambers, the biological sample having a meniscus that moves within the sample chambers during loading. The sample distribution network may further include a plurality of inlet channels, each inlet channel being in flow communication with and configured to flow biological sample to a respective sample chamber, and a plurality of outlet channels, each outlet channel being in flow communication and configured to flow biological sample from a respective sample chamber. At least some of the sample chambers may include a physical modification configured to control the movement of the meniscus so as to control bubble formation within the at least some sample chambers. At least some of the sample chambers may include a dried reagent positioned within the at least some sample chambers proximate the inlet channels in flow communication with the at least some sample chambers.

20070280857, Dec 6, 2007

Jun 2, 2006

11/422058

Maengseok Song - Burlingame CA, US
Joon Mo Yang - Redwood City CA, US
Julie C. Lee - Sunnyvale CA, US
Nigel P. Beard - Redwood City CA, US
Yuh-Min Chiang - Foster City CA, US
Roy H. Tan - Union City CA, US
Carol Schembri - San Mateo CA, US

APPLERA CORPORATION - Foster City CA

B01L 3/02

422100

A microfluidic device may include a sample distribution network including a plurality of sample chambers configured to be loaded with biological sample for biological testing of the biological sample while in the sample chambers, the biological sample having a meniscus that moves within the sample chambers during loading. The sample distribution network may further include a plurality of inlet channels, each inlet channel being in flow communication with and configured to flow biological sample to a respective sample chamber, and a plurality of outlet channels, each outlet channel being in flow communication and configured to flow biological sample from a respective sample chamber. At least some of the sample chambers may include a physical modification configured to control the movement of the meniscus so as to control bubble formation within the at least some sample chambers. At least some of the sample chambers may include a dried reagent positioned within the at least some sample chambers proximate the inlet channels in flow communication with the at least some sample chambers.

20090202631, Aug 13, 2009

Apr 22, 2009

12/428422

Nyomi V. Yam - Sunnyvale CA, US
Iran Reyes - San Jose CA, US
Nipun Davar - Fremont CA, US
Atul D. Ayer - Palo Alto CA, US
Julie Lee - Sunnyvale CA, US
Sonya Seroff - San Jose CA, US
Suneel K. Gupta - Sunnyvale CA, US
Gayatri Sathyan - San Jose CA, US

A61K 31/519
A61K 9/20

424464, 51425941

Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.